"Purines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
| Descriptor ID |
D011687
|
| MeSH Number(s) |
D03.633.100.759
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Purines".
Below are MeSH descriptors whose meaning is more specific than "Purines".
This graph shows the total number of publications written about "Purines" by people in this website by year, and whether "Purines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 10 | 10 | 20 |
| 2018 | 10 | 16 | 26 |
| 2019 | 3 | 6 | 9 |
| 2020 | 4 | 24 | 28 |
| 2021 | 9 | 10 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Purines" by people in Profiles.
-
Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas? Clin Infect Dis. 2021 12 06; 73(11):e3977-e3978.
-
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Clin Infect Dis. 2021 12 06; 73(11):e3978-e3979.
-
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al. Clin Infect Dis. 2021 12 06; 73(11):e3980-e3981.
-
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021 10 02; 60(10):e371.
-
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1407-1418.
-
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021 12; 9(12):1349-1351.
-
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. Respir Investig. 2021 Nov; 59(6):799-803.
-
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Oct; 99:108027.
-
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Biochem J. 2021 07 16; 478(13):2481-2497.
-
Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021 10; 69(10):2752-2758.